Oxidative modification of NK30424A and B enhance inhibitory effect on lipopolysaccharide-induced tumour necrosis factor-alpha promoter activity.
Takayasu
Yoshiyuki
Y
Research and Development Division, Pharmaceuticals Group, Nippon Kayaku Co, Ltd, Tokyo, Japan. yoshiyuki.takayasu@nipponkayaku.co.jp
Tsuchiya
Kouichi
K
Sukenaga
Yoshikazu
Y
D000818:Animals; D002460:Cell Line; D003545:Cysteine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D007783:Lactones / Q000737:chemistry* / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D008264:Macrophages; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D010084:Oxidation-Reduction; D011401:Promoter Regions, Genetic / Q000187:drug effects* / Q000235:genetics; D014162:Transfection; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics* / Q000378:metabolism
D007783:Lactones; D008070:Lipopolysaccharides; C449032:NK30424A; D014409:Tumor Necrosis Factor-alpha; D003545:Cysteine